Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2013, Article ID 823528, 14 pages
http://dx.doi.org/10.1155/2013/823528
Research Article

In Vivo Characterization of a Novel -Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects

1Department of Neuroscience, Merck Research Laboratories, Kenilworth, NJ 07033, USA
2Department of Molecular Biomarkers, Merck Research Laboratories, Kenilworth, NJ 07033, USA
3Department of Medicinal Chemistry, Merck Research Laboratories, Kenilworth, NJ 07033, USA
4Department of Drug Metabolism and Pharmoackinetics, Merck Research Laboratories, Kenilworth, NJ 07033, USA

Received 29 August 2012; Accepted 27 November 2012

Academic Editor: Jeremy Toyn

Copyright © 2013 Lynn A. Hyde et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Selkoe, “The molecular pathology of Alzheimer's disease,” Neuron, vol. 6, no. 4, pp. 487–498, 1991. View at Publisher · View at Google Scholar · View at Scopus
  2. J. A. Hardy and G. A. Higgins, “Alzheimer's disease: the amyloid cascade hypothesis,” Science, vol. 256, no. 5054, pp. 184–185, 1992. View at Google Scholar · View at Scopus
  3. J. Hardy and D. J. Selkoe, “The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. D. M. Barten, J. E. Meredith Jr., R. Zaczek, J. G. Houston, and C. F. Albright, “γ-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity,” Drugs in R and D, vol. 7, no. 2, pp. 87–97, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. L. A. Hyde, N. A. McHugh, J. Chen et al., “Studies to investigate the in vivo therapeutic window of the γ-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2- hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d] azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse,” Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 3, pp. 1133–1143, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. J. D. Best, M. T. Jay, F. Otu et al., “In vivo characterization of Aβ(40) changes in brain and cerebrospinal fluid using the novel γ-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1- trifluoromethanesulfonamide (MRK-560) in the rat,” Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 2, pp. 786–790, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. C. V. C. Prasad, M. Zheng, S. Vig et al., “Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)- N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a γ-secretase inhibitor with Aβ lowering activity in a transgenic mouse model of Alzheimer's disease,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 14, pp. 4006–4011, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. R. L. Martone, H. Zhou, K. Atchison- et al., “Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease,” Journal of Pharmacology and Experimental Therapeutics, vol. 331, no. 2, pp. 598–608, 2009. View at Google Scholar
  9. K. W. Gillman, J. E. Starrett, M. F. Parker et al., “Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable I^3-Secretase Inhibitor,” ACS Medicinal Chemistry Letters, vol. 1, no. 3, p. 120, 2010. View at Google Scholar
  10. G. S. Basi, S. Hemphill, E. F. Brigham et al., “Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease,” Alzheimer's Research & Therapy, vol. 2, no. 6, p. 36, 2010. View at Google Scholar
  11. T. A. Lanz, K. M. Wood, K. E. G. Richter et al., “Pharmacodynamics and pharmacokinetics of the γ-secretase inhibitor PF-3084014,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 1, pp. 269–277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Mitani, J. Yarimizu, K. Saita et al., “Differential effects between gamma-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice,” Journal of Neuroscience, vol. 32, no. 6, pp. 2037–2050, 2012. View at Google Scholar
  13. D. B. Henley, P. C. May, R. A. Dean, and E. R. Siemers, “Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease,” Expert Opinion on Pharmacotherapy, vol. 10, no. 10, pp. 1657–1664, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. R. J. Bateman, E. R. Siemers, K. G. Mawuenyega et al., “A γ-secretase inhibitor decreases amyloid-β production in the central nervous system,” Annals of Neurology, vol. 66, no. 1, pp. 48–54, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Tong, J. S. Wang, O. Sverdlov et al., “Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral gamma-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers,” Clinical Therapeutics, vol. 34, no. 3, pp. 654–667, 2012. View at Google Scholar
  16. A. S. Fleisher, R. Raman, E. R. Siemers et al., “Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease,” Archives of Neurology, vol. 65, no. 8, pp. 1031–1038, 2008. View at Google Scholar
  17. E. R. Siemers, J. F. Quinn, J. Kaye et al., “Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease,” Neurology, vol. 66, no. 4, pp. 602–604, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. J. D. Best, D. W. Smith, M. A. Reilly et al., “The novel γ secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]- 4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse,” Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 2, pp. 552–558, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Abramowski, K. H. Wiederhold, U. Furrer et al., “Dynamics of Aβ turnover and deposition in different β-amyloid precursor protein transgenic mouse models following γ-secretase inhibition,” Journal of Pharmacology and Experimental Therapeutics, vol. 327, no. 2, pp. 411–424, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. S. J. Pollack and H. Lewis, “γ-Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease,” Current Opinion in Investigational Drugs, vol. 6, no. 1, pp. 35–47, 2005. View at Google Scholar · View at Scopus
  21. A. Lleo and C. A. Saura, “gamma-secretase substrates and their implications for drug development in Alzheimer's disease,” Current Topics in Medicinal Chemistry, vol. 11, no. 12, pp. 1513–1527, 2011. View at Google Scholar
  22. B. De Strooper, W. Annaert, P. Cupers et al., “A presenilin-1-dependent γ-secretase-like protease mediates release of notch intracellular domain,” Nature, vol. 398, no. 6727, pp. 518–522, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Artavanis-Tsakonas, M. D. Rand, and R. J. Lake, “Notch signaling: cell fate control and signal integration in development,” Science, vol. 284, no. 5415, pp. 770–776, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. D. C. Cole, J. R. Stock, A. F. Kreft et al., “(S)-N-(5-Chlorothiophene-2-sulfonyl)-β,β-diethylalaninol a Notch-1-sparing γ-secretase inhibitor,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 3, pp. 926–929, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Kreft, B. Harrison, S. Aschmies et al., “Discovery of a novel series of Notch-sparing γ-secretase inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 14, pp. 4232–4236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. C. Mayer, A. F. Kreft, B. Harrison et al., “Discovery of begacestat, a Notch-1-sparing γ-secretase inhibitor for the treatment of Alzheimer's disease,” Journal of Medicinal Chemistry, vol. 51, no. 23, pp. 7348–7351, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. G. H. Searfoss, W. H. Jordan, D. O. Calligaro et al., “Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor,” Journal of Biological Chemistry, vol. 278, no. 46, pp. 46107–46116, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. G. T. Wong, D. Manfra, F. M. Poulet et al., “Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation,” Journal of Biological Chemistry, vol. 279, no. 13, pp. 12876–12882, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Milano, J. McKay, C. Dagenais et al., “Modulation of Notch processing by γ-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation,” Toxicological Sciences, vol. 82, no. 1, pp. 341–358, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. J. H. Van Es, M. E. Van Gijn, O. Riccio et al., “Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells,” Nature, vol. 435, no. 7044, pp. 959–963, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Katoh and M. Katoh, “Notch signaling in gastrointestinal tract (Review),” International Journal of Oncology, vol. 30, no. 1, pp. 247–251, 2007. View at Google Scholar · View at Scopus
  32. H. Zheng, D. M. Pritchard, X. Yang et al., “KLF4 gene expression is inhibited by the notch signaling pathway that controls goblet cell differentiation in mouse gastrointestinal tract,” American Journal of Physiology, vol. 296, no. 3, pp. G490–G498, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. C. A. Richmond and D. T. Breault, “Regulation of gene expression in the intestinal epithelium,” Progress in Molecular Biology and Translational Science, vol. 96, pp. 207–229, 2010. View at Google Scholar
  34. T. Asberom, Z. Zhao, T. A. Bara et al., “Discovery of γ-secretase inhibitors efficacious in a transgenic animal model of Alzheimer's disease,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 2, pp. 511–516, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. M. A. Chishti, D. S. Yang, C. Janus et al., “Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695,” Journal of Biological Chemistry, vol. 276, no. 24, pp. 21562–21570, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. L. A. Hyde, T. M. Kazdoba, M. Grilli et al., “Age-progressing cognitive impairments and neuropathology in transgenic CRND8 mice,” Behavioural Brain Research, vol. 160, no. 2, pp. 344–355, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. T. A. Lanz, C. S. Himes, G. Pallante et al., “The γ-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-lalanyl]-S-phenylglycine t-butyl ester reduces Aβ levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 305, no. 3, pp. 864–871, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. D. M. Barten, V. L. Guss, J. A. Corsa et al., “Dynamics of β-amyloid reductions in brain, cerebrospinal fluid, and plasma of β-amyloid precursor protein transgenic mice treated with a γ-secretase inhibitor,” Journal of Pharmacology and Experimental Therapeutics, vol. 312, no. 2, pp. 635–643, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Zhang, L. Song, G. Terracina, Y. Liu, B. Pramanik, and E. Parker, “Biochemical characterization of the γ-secretase activity that produces β-amyloid peptides,” Biochemistry, vol. 40, no. 16, pp. 5049–5055, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. C. R. Burton, J. E. Meredith, D. M. Barten et al., “The amyloid-β rise and γ-secretase inhibitor potency depend on the level of substrate expression,” Journal of Biological Chemistry, vol. 283, no. 34, pp. 22992–23003, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Jensen, E. E. Pedersen, P. Galante et al., “Control of endodermal endocrine development by Hes-1,” Nature Genetics, vol. 24, no. 1, pp. 36–44, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Fre, M. Huyghe, P. Mourikis, S. Robine, D. Louvard, and S. Artavanis-Tsakonas, “Notch signals control the fate of immature progenitor cells in the intestine,” Nature, vol. 435, no. 7044, pp. 964–968, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Das, C. Verbeeck, L. Minter et al., “Transient pharmacologic lowering of Abeta production prior to deposition results in sustained reduction of amyloid plaque pathology,” Molecular Neurodegeneration, vol. 7, p. 39, 2012. View at Google Scholar
  44. T. A. Lanz, M. J. Karmilowicz, K. M. Wood et al., “Concentration-dependent modulation of amyloid-β in vivo and in vitro using the γ-secretase inhibitor, LY-450139,” Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 2, pp. 924–933, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Siemers, M. Skinner, R. A. Dean et al., “Safety, tolerability, and changes in amyloid β concentrations after administration of a γ-secretase inhibitor in volunteers,” Clinical Neuropharmacology, vol. 28, no. 3, pp. 126–132, 2005. View at Publisher · View at Google Scholar · View at Scopus